Expression of urotensin-II in human coronary atherosclerosis
- PMID: 16026900
- DOI: 10.1016/j.peptides.2005.05.028
Expression of urotensin-II in human coronary atherosclerosis
Abstract
The vasoactive peptide urotensin-II (U-II) is best known for its ability to regulate peripheral vascular and cardiac contractile function in vivo, and recent in vitro studies have suggested a role for the peptide in the control of vascular remodeling by inducing smooth muscle proliferation and fibroblast-mediated collagen deposition. Therefore, U-II may play a role in the etiology of atherosclerosis. In the present study we sought to determine the expression of U-II in coronary arteries from patients with coronary atherosclerosis and from normal control subjects, using immunohistochemistry and in situ hybridization. In normal coronary arteries, there was little expression of U-II in all types of cells. In contrast, in patients with coronary atherosclerosis, endothelial expression of U-II was significantly increased in all diseased segments (P<0.05). Greater expression of U-II was noted in endothelial cells of lesions with subendothelial inflammation or fibrofatty lesion compared with that of endothelial cells underlined by dense fibrosis or minimal intimal thickening. Myointimal cells and foam cells also expressed U-II. In most diseased segments, medial smooth muscle cells exhibited moderate expression of U-II. These findings demonstrate upregulation of U-II in endothelial, myointimal and medial smooth muscle cells of atherosclerotic human coronary arteries, and suggest a possible role for U-II in the pathogenesis of coronary atherosclerosis.
Similar articles
-
Urotensin-II and cardiovascular remodeling.Peptides. 2008 May;29(5):764-9. doi: 10.1016/j.peptides.2007.09.012. Epub 2007 Sep 29. Peptides. 2008. PMID: 17988761 Review.
-
Human urotensin II as a link between hypertension and coronary artery disease.Hypertens Res. 2006 Jun;29(6):375-87. doi: 10.1291/hypres.29.375. Hypertens Res. 2006. PMID: 16940699 Review.
-
Urotensin II and atherosclerosis.Peptides. 2008 May;29(5):778-82. doi: 10.1016/j.peptides.2007.08.024. Epub 2007 Sep 2. Peptides. 2008. PMID: 17933432 Review.
-
[Expression of urotensinII in human coronary artery and coronary atherosclerosis].Di Yi Jun Yi Da Xue Xue Bao. 2003 Jun;23(6):572-4. Di Yi Jun Yi Da Xue Xue Bao. 2003. PMID: 12810379 Chinese.
-
Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.J Pathol. 1999 Jun;188(2):180-8. doi: 10.1002/(SICI)1096-9896(199906)188:2<180::AID-PATH338>3.0.CO;2-Q. J Pathol. 1999. PMID: 10398162
Cited by
-
Effects of urotensin-II on cytokines in early acute liver failure in mice.World J Gastroenterol. 2015 Mar 21;21(11):3239-44. doi: 10.3748/wjg.v21.i11.3239. World J Gastroenterol. 2015. PMID: 25805930 Free PMC article.
-
Enhancement of vascular smooth muscle cell migration by urotensin II.Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):381-6. doi: 10.1007/s00210-006-0086-x. Epub 2006 Aug 1. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16896801
-
Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.Int J Biomed Sci. 2007 Mar;3(1):38-45. Int J Biomed Sci. 2007. PMID: 23675019 Free PMC article.
-
Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-α induced by urotensin II.J Zhejiang Univ Sci B. 2022 Dec 15;23(12):1014-1027. doi: 10.1631/jzus.B2200346. J Zhejiang Univ Sci B. 2022. PMID: 36518054 Free PMC article.
-
Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels.Clin Psychopharmacol Neurosci. 2019 May 31;17(2):211-221. doi: 10.9758/cpn.2019.17.2.211. Clin Psychopharmacol Neurosci. 2019. PMID: 30905121 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical